Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENERGI-F703 in Diabetic Foot Ulcers
NCT02672436Phase 2Completed
- Sponsor
- Energenesis Biomedical Co., Ltd.
- Start
- Mar 2017
- Primary completion
- Oct 2019
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic foot ulcer (DFU) comparing ENERGI-F703 with Placebo (2 arms). Primary endpoint: The ulcer closure rate at 12 weeks. Started Mar 2017; status: completed.
02
Drugs
ENERGI-F703
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT02672436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02672436.